Wedbush downgraded Werewolf Therapeutics (HOWL) to Neutral from Outperform with a price target of $1, down from $3. Published first on TheFly – ...

As of Wednesday, December 17, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 8.80%, which has investors questioning if this is right time to sell.

Citizens downgraded Werewolf Therapeutics (HOWL) to Market Perform from Outperform without a price target after the company provided updates to ...

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or ...

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...